Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (160)
  2. Journal Article (105)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (119)
  5. Department of Pathology and Laboratory Medicine (102)
  6. Human Oncology and Pathogenesis Program (100)

More Groups

People
  1. Gregory Riely (107)
  2. Mark Kris (94)
  3. Marc Ladanyi (71)
  4. Charles Rudin (57)
  5. Maria Arcila (55)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (14)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Journal of Thoracic Oncology (62)
  3. Annals of Oncology (26)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (84)
  2. American Society of Clinical Oncology (82)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (30)
  5. Nature Publishing Group (11)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (285)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
    Journal Article

    Hickman, R. A.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gewirtz, A. N.; more...
    Acta Neuropathologica Communications (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in previously untreated, advanced nonsquamous NSCLC patients with EGFR exon 20 insertions
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced NSCLC with exon 20 insertions and other uncommon EGFR mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Jayakrishnan, R.; Nassar, A.; Shepherd, F. A.; Lin, J. J.; Lin, S. H.; Shakya, P.; Dilling, T. J.; Bar, J.; Grohe, C.; Gupta, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer
    Meeting Abstract

    Quintanal-Villalonga, A.; Kawasaki, K.; Redin, E.; Rakhade, S.; Durani, V.; Sabet, A.; Karthaus, W.; Zaidi, S.; Zhan, Y. A.; Manoj, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save